Background and objective: The research term “interstitial pneumonia with autoimmune features” (IPAF) encompasses interstitial lung disease (ILD) patients with autoimmune features not meeting diagnostic criteria for a defined connective tissue disease (CTD). It remains unclear if IPAF is a distinct disease entity with implications for management and prognosis. We describe an Australian IPAF population and compare their baseline characteristics and outcomes with distinct cohorts of idiopathic interstitial pneumonia (IIP), CTD-ILD, and unclassifiable ILD. Methods: Review of 291 consecutive patients attending a specialist ILD clinic was performed. Patients with a diagnosis of IIP, CTD-ILD, and unclassifiable ILD by ILD-multidisciplinary meeting (ILD-MDM) were included. Patients meeting the IPAF criteria were identified. Baseline clinical data, survival, and progression were compared between ILD groups. Results: 226 patients were included, 36 meeting the IPAF criteria. IPAF patients demonstrated a high prevalence of autoantibodies to tRNA synthetase (35.3%), Ro52 (27.8%), and neutrophilic cytoplasmic antigens (ANCA; 20.0%). IPAF and CTD-ILD patients demonstrated similar clinical characteristics (mean age 66.6 and 63.7 years, respectively, female predominant, frequent CTD-manifestations). Lung function did not differ between ILD groups. Disease severity, pulmonary hypertension (PH), and ILD-MDM diagnosis were strong predictors of worse transplant-free survival (TFS). Meeting the IPAF criteria was not associated with TFS. Conclusions: We identified IPAF as a heterogeneous phenotype that overlaps considerably with CTD-ILD. Disease severity, PH, and ILD-MDM diagnosis were more powerful predictors of survival outcomes than meeting the IPAF criteria.

1.
Cottin
V
,
Hirani
NA
,
Hotchkin
DL
,
Nambiar
AM
,
Ogura
T
,
Otaola
M
,
Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases
.
Eur Respir Rev
.
2018
;
27
(
150
):
180076
.
2.
Raghu
G
,
Collard
HR
,
Egan
JJ
,
Martinez
FJ
,
Behr
J
,
Brown
KK
,
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
.
Am J Respir Crit Care Med
.
2011
;
183
(
6
):
788
824
. .
3.
Idiopathic Pulmonary Fibrosis Clinical Research Network
,
Raghu
G
,
Anstrom
KJ
,
King
TE
,
Lasky
JA
,
Martinez
FJ
.
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis
.
N Engl J Med
.
2012
;
366
(
21
):
1968
77
.
4.
Fischer
A
,
Antoniou
KM
,
Brown
KK
,
Cadranel
J
,
Corte
TJ
,
du Bois
RM
,
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
.
Eur Respir J
.
2015
;
46
(
4
):
976
87
. .
5.
Oldham
JM
,
Adegunsoye
A
,
Valenzi
E
,
Lee
C
,
Witt
L
,
Chen
L
,
Characterisation of patients with interstitial pneumonia with autoimmune features
.
Eur Respir J
.
2016
;
47
(
6
):
1767
75
. .
6.
Chartrand
S
,
Swigris
JJ
,
Stanchev
L
,
Lee
JS
,
Brown
KK
,
Fischer
A
.
Clinical features and natural history of interstitial pneumonia with autoimmune features: a single center experience
.
Respir Med
.
2016
;
119
:
150
4
. .
7.
Ahmad
K
,
Barba
T
,
Gamondes
D
,
Ginoux
M
,
Khouatra
C
,
Spagnolo
P
,
Interstitial pneumonia with autoimmune features: clinical, radiologic, and histological characteristics and outcome in a series of 57 patients
.
Respir Med
.
2017
;
123
:
56
62
. .
8.
Ito
Y
,
Arita
M
,
Kumagai
S
,
Takei
R
,
Noyama
M
,
Tokioka
F
,
Serological and morphological prognostic factors in patients with interstitial pneumonia with autoimmune features
.
BMC Pulm Med
.
2017
;
17
(
1
):
111
. .
9.
Dai
J
,
Wang
L
,
Yan
X
,
Li
H
,
Zhou
K
,
He
J
,
Clinical features, risk factors, and outcomes of patients with interstitial pneumonia with autoimmune features: a population-based study
.
Clin Rheumatol
.
2018
;
37
:
2125
32
.
10.
Yoshimura
K
,
Kono
M
,
Enomoto
Y
,
Nishimoto
K
,
Oyama
Y
,
Yasui
H
,
Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia
.
Respir Med
.
2018
;
137
:
167
75
. .
11.
Kelly
BT
,
Moua
T
.
Overlap of interstitial pneumonia with autoimmune features with undifferentiated connective tissue disease and contribution of UIP to mortality
.
Respirology
.
2018
;
23
(
6
):
600
5
. .
12.
Graney
BA
,
Fischer
A
.
Interstitial pneumonia with autoimmune features
.
Ann Am Thorac Soc
.
2019
;
16
:
525
33
. .
13.
Travis
WD
,
Costabel
U
,
Hansell
DM
,
King
TE
 Jr.
,
Lynch
DA
,
Nicholson
AG
,
An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias
.
Am J Respir Crit Care Med
.
2013
;
188
(
6
):
733
48
. .
14.
Latsi
PI
,
du Bois
RM
,
Nicholson
AG
,
Colby
TV
,
Bisirtzoglou
D
,
Nikolakopoulou
A
,
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends
.
Am J Respir Crit Care Med
.
2003
;
168
(
5
):
531
7
. .
15.
Egan
JJ
,
Martinez
FJ
,
Wells
AU
,
Williams
T
.
Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification
.
Thorax
.
2005
;
60
(
4
):
270
3
. .
16.
Ryerson
CJ
,
Vittinghoff
E
,
Ley
B
,
Lee
JS
,
Mooney
JJ
,
Jones
KD
,
Predicting survival across chronic interstitial lung disease: the ILD-GAP model
.
Chest
.
2014
;
145
(
4
):
723
8
. .
17.
Wells
AU
,
Desai
SR
,
Rubens
MB
,
Goh
NS
,
Cramer
D
,
Nicholson
AG
,
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography
.
Am J Respir Crit Care Med
.
2003
;
167
(
7
):
962
9
. .
18.
Augustine
DX
,
Coates-Bradshaw
LD
,
Willis
J
,
Harkness
A
,
Ring
L
,
Grapsa
J
,
Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography
.
Echo Res Pract
.
2018
;
5
(
3
):
G11
24
. .
19.
Lim
JU
,
Gil
BM
,
Kang
HS
,
Oh
J
,
Kim
YH
,
Kwon
SS
.
Interstitial pneumonia with autoimmune features show better survival and less exacerbations compared to idiopathic pulmonary fibrosis
.
BMC Pulm Med
.
2019
;
19
(
1
):
120
. .
20.
Raghu
G
,
Remy-Jardin
M
,
Myers
JL
,
Richeldi
L
,
Ryerson
CJ
,
Lederer
DJ
,
Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline
.
Am J Respir Crit Care Med
.
2018
;
198
(
5
):
e44
68
. .
21.
Lega
JC
,
Reynaud
Q
,
Belot
A
,
Fabien
N
,
Durieu
I
,
Cottin
V
.
Idiopathic inflammatory myopathies and the lung
.
Eur Respir Rev
.
2015
;
24
(
136
):
216
38
. .
22.
Lilleker
JB
,
Vencovsky
J
,
Wang
G
,
Wedderburn
LR
,
Diederichsen
LP
,
Schmidt
J
,
The EuroMyositis registry: an international collaborative tool to facilitate myositis research
.
Ann Rheum Dis
.
2018
;
77
(
1
):
30
9
. .
23.
Aggarwal
R
,
Dhillon
N
,
Fertig
N
,
Koontz
D
,
Qi
Z
,
Oddis
CV
.
A negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of anticytoplasmic antibody as a screening test for antisynthetase syndrome
.
J Rheumatol
.
2017
;
44
(
2
):
223
9
. .
24.
Fidler
L
,
Doubelt
I
,
Kandel
S
,
Fisher
JH
,
Mittoo
S
,
Shapera
S
.
Screening for myositis antibodies in idiopathic interstitial lung disease
.
Lung
.
2019
;
197
(
3
):
277
84
. .
25.
La Corte
R
,
Lo Mo Naco
A
,
Locaputo
A
,
Dolzani
F
,
Trotta
F
.
In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease
.
Autoimmunity
.
2006
;
39
(
3
):
249
53
. .
26.
Marie
I
,
Hatron
PY
,
Dominique
S
,
Cherin
P
,
Mouthon
L
,
Menard
JF
,
Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody
.
Semin Arthritis Rheum
.
2012
;
41
(
6
):
890
9
. .
27.
Hozumi
H
,
Oyama
Y
,
Yasui
H
,
Suzuki
Y
,
Kono
M
,
Karayama
M
,
Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias
.
PLoS One
.
2018
;
13
(
6
):
e0199659
. .
28.
Hudson
M
,
Pope
J
,
Mahler
M
,
Tatibouet
S
,
Steele
R
,
Baron
M
,
Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis
.
Arthritis Res Ther
.
2012
;
14
(
2
):
R50
. .
29.
Shi
J
,
Li
S
,
Yang
H
,
Zhang
Y
,
Peng
Q
,
Lu
X
,
Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies
.
J Rheumatol
.
2017
;
44
(
7
):
1051
7
. .
30.
Alba
MA
,
Flores-Suárez
LF
,
Henderson
AG
,
Xiao
H
,
Hu
P
,
Nachman
PH
,
Interstital lung disease in ANCA vasculitis
.
Autoimmun Rev
.
2017
;
16
(
7
):
722
9
. .
31.
Vij
R
,
Strek
ME
.
Diagnosis and treatment of connective tissue disease-associated interstitial lung disease
.
Chest
.
2013
;
143
(
3
):
814
24
. .
32.
Song
JW
,
Do
KH
,
Kim
MY
,
Jang
SJ
,
Colby
TV
,
Kim
DS
.
Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia
.
Chest
.
2009
;
136
(
1
):
23
30
. .
33.
Park
JH
,
Kim
DS
,
Park
IN
,
Jang
SJ
,
Kitaichi
M
,
Nicholson
AG
,
Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes
.
Am J Respir Crit Care Med
.
2007
;
175
(
7
):
705
11
. .
34.
Dinse
GE
,
Parks
CG
,
Weinberg
CR
,
Meier
HCS
,
Co
CA
,
Chan
EKL
,
Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999–2004)
.
PLoS One
.
2017
;
12
(
10
):
e0185977
.
35.
Selmi
C
,
Ceribelli
A
,
Generali
E
,
Scirè
CA
,
Alborghetti
F
,
Colloredo
G
,
Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years
.
Autoimmun Rev
.
2016
;
15
(
2
):
162
6
. .
36.
Maher
TM
,
Corte
TJ
,
Fischer
A
,
Kreuter
M
,
Lederer
DJ
,
Molina-Molina
M
,
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
.
Lancet Respir Med
.
2019
;
8
:
P147
57
. .
37.
Distler
O
,
Highland
KB
,
Gahlemann
M
,
Azuma
A
,
Fischer
A
,
Mayes
MD
,
Nintedanib for systemic sclerosis–associated interstitial lung disease
.
New Engl J Med
.
2019
;
380
:
2518
28
. .
38.
Flaherty
KR
,
Wells
AU
,
Cottin
V
,
Devaraj
A
,
Walsh
SLF
,
Inoue
Y
,
Nintedanib in progressive fibrosing interstitial lung diseases
.
New Engl J Med
.
2019
;
381
:
1718
27
. .
39.
Hutchinson
JP
,
Fogarty
AW
,
McKeever
TM
,
Hubbard
RB
.
In-Hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011
.
Am J Respir Crit Care Med
.
2016
;
193
(
10
):
1161
7
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.